Cocrystal PharmaCOCP -3.35%25 PB Ratio is 3.38 as of Jun. 26, 2026, which is 483% above its 10-year median of 0.58. GuruFocus rates COCP with a GF Score™ of 25/100. The stock has 3 warning signs investors should review. Among 1,232 Biotechnology companies, Cocrystal Pharma ranks worse than 58.12% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Cocrystal Pharma's share price is $1.01. Cocrystal Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was $0.30. Hence, Cocrystal Pharma's PB Ratio of today is 3.38.
The historical rank and industry rank for Cocrystal Pharma's PB Ratio or its related term are showing as below:
COCP'
s PB Ratio Range Over the Past 10 Years
Min: 0.09 Med: 0.58 Max: 5.08
Current: 3.38
During the past 13 years, Cocrystal Pharma's highest PB Ratio was 5.08. The lowest was 0.09. And the median was 0.58.
COCP's PB Ratio is ranked worse than 58.12% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs COCP: 3.38
During the past 12 months, Cocrystal Pharma's average Book Value Per Share Growth Rate was -58.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -54.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -47.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -39.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Cocrystal Pharma was 38.60% per year. The lowest was -70.80% per year. And the median was -39.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cocrystal Pharma PB Ratio Related Terms
Cocrystal Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Cocrystal Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cocrystal Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cocrystal Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cocrystal Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cocrystal Pharma (COCP) has a PB Ratio of 3.38 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cocrystal Pharma and its competitors. This is 483% above median its historical median of 0.58. Over the past decade, Cocrystal Pharma's PB Ratio has ranged from 0.09 to 5.08. According to the industry distribution chart, Cocrystal Pharma ranks #716 out of 1232 companies in the Biotechnology industry, placing it in the top 58.1%.
Is Cocrystal Pharma's PB Ratio too high?
Cocrystal Pharma's current PB Ratio of 3.38 is 483% above median its 10-year median of 0.58. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 5.08. The Biotechnology industry median PB Ratio is 2.80. Cocrystal Pharma's value of 3.38 is 20.7% above this industry median. Based on the distribution chart, Cocrystal Pharma ranks #716 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cocrystal Pharma has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cocrystal Pharma's PB Ratio compare to OSRH and CVKD?
According to the Biotechnology industry distribution chart, Cocrystal Pharma ranks #716 out of 1232 companies for PB Ratio. This places Cocrystal Pharma in the lower half of its industry. The industry median PB Ratio is 2.80. Cocrystal Pharma's value of 3.38 is 20.7% above this benchmark. Historically, Cocrystal Pharma's own PB Ratio has ranged from 0.09 to 5.08 over the past decade. While the company's 10-year median is 0.58 vs. the industry median of 2.80, Cocrystal Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cocrystal Pharma's current PB Ratio of 3.38 is 20.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cocrystal Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cocrystal Pharma's current PB Ratio is 3.38, which is 483% above median its own 10-year median of 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cocrystal Pharma stock overvalued right now?
Cocrystal Pharma (COCP) has a current PB Ratio of 3.38. The current PB Ratio is 3.38, which is 483% above median its 10-year median of 0.58 and 20.7% above the Biotechnology industry median of 2.80. Cocrystal Pharma's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cocrystal Pharma (COCP), the current PB Ratio is 3.38 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
25GF Score
Get the complete analysis for COCP
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COCP has been successfully added to your 
